Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate to severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
Andrew Alexis, MD, MPH
Advertisement
Andrew Alexis, MD, MPH, Professor of Clinical Dermatology and Vice Chair for Diversity and Inclusion in the Department of Dermatology at Weill Cornell Medicine, a dermatologist at New York-Presbyterian/Weill Cornell Medical Center and lead ADmirable investigator.
Articles by Andrew Alexis, MD, MPH
Advertisement
Latest Updated Articles
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitisPublished: June 25th 2025 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Redefining type 1 diabetes: Early identification, staging, and clinical implications for pediatric care
2
CDC updates website, opens door for autism and vaccines link
3
Practical reminders, considerations for anaphylaxis care, with Alice Hoyt, MD, FAAAI
4
